Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02116998
Other study ID # GEN-004-002
Secondary ID 2014-000944-13
Status Completed
Phase Phase 2
First received April 11, 2014
Last updated April 4, 2018
Start date September 2014
Est. completion date April 2016

Study information

Verified date April 2018
Source Genocea Biosciences, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive GEN-004 with adjuvant or placebo. Each subject will receive up to 3 doses at 4 week intervals.

Following the third dose, subjects will be inoculated intranasally with S. pneumoniae serotype 6B. Nasal washes to identify S. pneumoniae colonization will be obtained pre-inoculation, and then 2, 7 and 14 days after inoculation.

Subjects will also be monitored for safety and tolerability throughout the dosing period, and then for 12 months after their last dose.

The purpose of this study is to evaluate the effectiveness of GEN-004 in reducing colonization rates and magnitude of colonization following the S. pneumoniae challenge.


Recruitment information / eligibility

Status Completed
Enrollment 98
Est. completion date April 2016
Est. primary completion date April 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Males and non-pregnant females, ages 18 to 55 years inclusive.

- Willing and able to provide written informed consent.

- Fluent English speakers only (for safety reasons)

- Willing to perform and comply with all study procedures including attending clinic visits as scheduled.

Exclusion Criteria:

- Prior vaccination with pneumococcal vaccine.

- History of invasive pneumococcal disease (i.e., sepsis, meningitis or pneumonia with bacteremia).

- Close contact with at risk individuals (young children [under 5years], immunosuppressed adults, elderly, chronic ill health).

- Current smoker or significant smoking history (>10 pack years).

- Pregnant or breast-feeding woman.

- Women of child-bearing potential (WOCBP) who are deemed not to have sufficient, effective birth control in place for 1 month prior to vaccination and 1 month after the final vaccination.

- Allergy to penicillin or amoxicillin.

- Any screening laboratory value > Grade 1

- Positive serologic test for HIV-1 or hepatitis C infection; positive hepatitis B surface antigen (HBsAg).

- Asthma (on regular medication) or other respiratory disease.

- Immunocompromised individuals, including those receiving corticosteroids or other immunosuppressive agents.

- Presence or history of auto-immune disease (refer to Appendix 4) regardless of current treatment.

- No antibiotic treatment within 1 week of inoculation

- Previous involvement in EHPC study inoculated with pneumococcal bacteria

- In any other clinical trial unless in observational stage or follow-up

- Diabetes, type 1 or type 2.

- Other active, uncontrolled co-morbidities that, in the opinion of the Investigator would make the subject unsuitable for the study or unable to comply with the study requirements.

NOTE: Subjects who are taking a medication to control an underlying co-morbidity may be enrolled if there have been no changes to their medication within 60 days prior to first dose of Study Drug.

Study Design


Intervention

Biological:
GEN-004 with Aluminum Hydroxide Adjuvant
GEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection. GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens: GB104: ABC transporter, substrate-binding protein GB144: Maltose/maltodextrin binding protein, ABC transporter GB152: Hypothetical protein GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen). Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL.
Placebo
Placebo: normal saline, 0.5 mL per dose, IM.
Streptococcus pneumoniae inoculation
Intranasal inoculation of S. Pneumoniae (80,000 CFU/100µl per nostril) serotype 6B.

Locations

Country Name City State
United Kingdom Royal Liverpool University Hospital, Liverpool School of Tropical Medicine Liverpool

Sponsors (1)

Lead Sponsor Collaborator
Genocea Biosciences, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of GEN-004 with aluminum hydroxide in healthy adult subjects to reduce nasopharyngeal colonization following intranasal inoculation with S. pneumoniae serotype 6 as measured by proportion of colonized subjects 56 weeks
Secondary Safety and tolerability of GEN-004 with aluminum hydroxide 56 weeks
Secondary Duration of S. pneumoniae colonization through 14 days after inoculation 12 weeks
Secondary Immunogenicity of GEN-004 with aluminum hydroxide, as measured by TH17 (IL-17) and IgG responses to the vaccine antigens in sera and nasal fluid 56 weeks
Secondary Impact of GEN-004 on the density of colonization as measured by S. pneumoniae colony forming units (CFUs) post-inoculation 56 weeks
See also
  Status Clinical Trial Phase
Completed NCT02201030 - Immunogenicity and Safety Study of NBP606 in Healthy Infants Phase 3
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Completed NCT04031846 - Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) Phase 3
Recruiting NCT05920499 - The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage N/A
Completed NCT01215175 - Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001) Phase 1
Completed NCT02892812 - A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults Phase 1
Completed NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants Phase 1
Completed NCT01193582 - A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria Phase 4
Completed NCT00744263 - Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults Phase 4
Completed NCT00492557 - Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults Phase 3
Completed NCT00195611 - Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media Phase 4
Completed NCT00205803 - Study Evaluating Pneumococcal Vaccine in Healthy Infants Phase 1/Phase 2
Completed NCT00137605 - Early Versus Delayed Pneumococcal Vaccination in HIV Phase 1/Phase 2
Completed NCT02531373 - A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005) Phase 1/Phase 2
Completed NCT03615482 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) Phase 3
Completed NCT03565900 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) Phase 3
Completed NCT04989465 - A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine Phase 4
Completed NCT02547649 - Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) Phase 2
Completed NCT02573181 - Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007) Phase 2
Completed NCT05477693 - Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine Phase 4